Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Enhancing the Drug Release and Physicochemical Properties of Rivaroxaban via Cyclodextrin Complexation: A Comprehensive Analytical Approach

C. Solomon, V. Anuța, I. Sarbu, EA. Ozon, AM. Musuc, V. Bratan, A. Rusu, VA. Surdu, C. Croitoru, A. Chandak, RM. Gavriloaia, TD. Balaci, DT. Niță, MA. Mitu

. 2025 ; 18 (6) : . [pub] 20250522

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25014319

Background/Objectives: Rivaroxaban, an oral anticoagulant, shows poor aqueous solubility, posing significant challenges to its bioavailability and therapeutic efficiency. The present study investigates the improvement of rivaroxaban's solubility through the formation of different inclusion complexes with three cyclodextrin derivatives, such as β-cyclodextrin (β-CD), methyl-β-cyclodextrin (Me-β-CD), and hydroxypropyl-β-cyclodextrin (HP-β-CD) prepared by lyophilization in order to stabilize the complexes and improve dissolution characteristics of rivaroxaban. Methods: The physicochemical properties of the individual compounds and the three lyophilized complexes were analysed using Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), X-ray diffraction (XRD), and thermogravimetric analysis (TGA). Results: FTIR spectra confirmed the formation of non-covalent interactions between rivaroxaban and the cyclodextrins, suggesting successful encapsulation into cyclodextrin cavity. SEM images revealed a significant morphological transformation from the crystalline structure of pure rivaroxaban and cyclodextrins morphologies to a more porous and amorphous matrix in all lyophilized complexes. XRD patterns indicated a noticeable reduction in drug crystallinity, supporting enhanced potential of the drug solubility. TGA analysis demonstrated improved thermal stability in the inclusion complexes compared to the individual drug and cyclodextrins. Pharmacotechnical evaluation revealed that the obtained formulations (by comparison with physical mixtures formulations) possessed favorable bulk and tapped density values, suitable compressibility index, and good flow properties, making all suitable for direct compression into solid dosage forms. Conclusions: The improved cyclodextrins formulation characteristics, combined with enhanced dissolution profiles of rivaroxaban comparable to commercial Xarelto® 10 mg, highlight the potential of both cyclodextrin inclusion and lyophilization technique as synergistic strategies for enhancing the solubility and drug release of rivaroxaban.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014319
003      
CZ-PrNML
005      
20250905141336.0
007      
ta
008      
250701s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ph18060761 $2 doi
035    __
$a (PubMed)40573162
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Solomon, Cristina $u Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia St., 020956 Bucharest, Romania
245    10
$a Enhancing the Drug Release and Physicochemical Properties of Rivaroxaban via Cyclodextrin Complexation: A Comprehensive Analytical Approach / $c C. Solomon, V. Anuța, I. Sarbu, EA. Ozon, AM. Musuc, V. Bratan, A. Rusu, VA. Surdu, C. Croitoru, A. Chandak, RM. Gavriloaia, TD. Balaci, DT. Niță, MA. Mitu
520    9_
$a Background/Objectives: Rivaroxaban, an oral anticoagulant, shows poor aqueous solubility, posing significant challenges to its bioavailability and therapeutic efficiency. The present study investigates the improvement of rivaroxaban's solubility through the formation of different inclusion complexes with three cyclodextrin derivatives, such as β-cyclodextrin (β-CD), methyl-β-cyclodextrin (Me-β-CD), and hydroxypropyl-β-cyclodextrin (HP-β-CD) prepared by lyophilization in order to stabilize the complexes and improve dissolution characteristics of rivaroxaban. Methods: The physicochemical properties of the individual compounds and the three lyophilized complexes were analysed using Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), X-ray diffraction (XRD), and thermogravimetric analysis (TGA). Results: FTIR spectra confirmed the formation of non-covalent interactions between rivaroxaban and the cyclodextrins, suggesting successful encapsulation into cyclodextrin cavity. SEM images revealed a significant morphological transformation from the crystalline structure of pure rivaroxaban and cyclodextrins morphologies to a more porous and amorphous matrix in all lyophilized complexes. XRD patterns indicated a noticeable reduction in drug crystallinity, supporting enhanced potential of the drug solubility. TGA analysis demonstrated improved thermal stability in the inclusion complexes compared to the individual drug and cyclodextrins. Pharmacotechnical evaluation revealed that the obtained formulations (by comparison with physical mixtures formulations) possessed favorable bulk and tapped density values, suitable compressibility index, and good flow properties, making all suitable for direct compression into solid dosage forms. Conclusions: The improved cyclodextrins formulation characteristics, combined with enhanced dissolution profiles of rivaroxaban comparable to commercial Xarelto® 10 mg, highlight the potential of both cyclodextrin inclusion and lyophilization technique as synergistic strategies for enhancing the solubility and drug release of rivaroxaban.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Anuța, Valentina $u Innovative Therapeutic Structures Research and Development Centre (InnoTher), "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia Street, 020956 Bucharest, Romania $1 https://orcid.org/0000000312665862
700    1_
$a Sarbu, Iulian $u Faculty of Pharmacy, "Titu Maiorescu" University, 004051 Bucharest, Romania $1 https://orcid.org/000000022259647X
700    1_
$a Ozon, Emma Adriana $u Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia St., 020956 Bucharest, Romania
700    1_
$a Musuc, Adina Magdalena $u Institute of Physical Chemistry-Ilie Murgulescu, Romanian Academy, 060021 Bucharest, Romania $1 https://orcid.org/0000000269358065
700    1_
$a Bratan, Veronica $u Institute of Physical Chemistry-Ilie Murgulescu, Romanian Academy, 060021 Bucharest, Romania
700    1_
$a Rusu, Adriana $u Institute of Physical Chemistry-Ilie Murgulescu, Romanian Academy, 060021 Bucharest, Romania
700    1_
$a Surdu, Vasile-Adrian $u Department of Materials Science, Faculty of Materials Science and Engineering, Transilvania University of Brasov, 29 Eroilor Blvd., 500036 Brasov, Romania $1 https://orcid.org/0000000242075380
700    1_
$a Croitoru, Cătălin $u Materials Engineering and Welding Department, Transilvania University of Brasov, 500036 Brasov, Romania $1 https://orcid.org/0000000185056510
700    1_
$a Chandak, Abhay $u Zentiva Group, U Kabelovny 529/16, 102 00 Praha-Dolní Měcholupy, Czech Republic
700    1_
$a Gavriloaia, Roxana Mariuca $u Faculty of Pharmacy, "Titu Maiorescu" University, 004051 Bucharest, Romania $1 https://orcid.org/000900096296663X
700    1_
$a Balaci, Teodora Dalila $u Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia St., 020956 Bucharest, Romania
700    1_
$a Niță, Denisa Teodora $u Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia St., 020956 Bucharest, Romania
700    1_
$a Mitu, Mirela Adriana $u Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia St., 020956 Bucharest, Romania $1 https://orcid.org/0000000228317574
773    0_
$w MED00184066 $t Pharmaceuticals $x 1424-8247 $g Roč. 18, č. 6 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40573162 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141324 $b ABA008
999    __
$a ok $b bmc $g 2388046 $s 1251439
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 18 $c 6 $e 20250522 $i 1424-8247 $m Pharmaceuticals $n Pharmaceuticals (Basel) $x MED00184066
LZP    __
$a Pubmed-20250701

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace